NO1, a New Sigma 2 Receptor/TMEM97 Fluorescent Ligand, Downregulates SOCE and Promotes Apoptosis in the Triple Negative Breast Cancer Cell Lines
By Carlos Cantonero, Pedro Javier Camello, Carmen Abate, Francesco Berardi, Gines Maria Salido, Juan Antonio Rosado, and Pedro C. Redondo
Excerpt from the article published in Cancers. 2020; 12(2):257. DOI: https://doi.org/10.3390/cancers12020257
Editor’s Highlights
- Cancer cell proliferation results from a dysregulated cell cycle and an impaired cell-death signaling mechanism, where changes in the cytosolic free-Ca2+ concentration play a relevant role.
- Store-operated Ca2+ entry (SOCE) is considered as a major Ca2+-entry mechanism in nonelectrically excited cells; it is regulated by emptying of the intracellular Ca2+ stores, such as the endoplasmic reticulum (ER).
- SOCE depends on STIM1, STIM2, and Orai3, whereas in MDA-MB-231 cells, STIM1 activates Ca2+ entry through Orai1.
- Sigma-2 receptor (σ2R/TMEM97) regulates the intracellular Ca2+ homeostasis and downregulates SOCE by impairing the interaction with STIM1, which may be required for its interaction with Orai1.
- σ2R/TMEM97 agonists have a relevant functional role on triple-negative breast cancer cells (TNBCs) which agrees with previous results obtained in other cell models
- A ligand of σ2R/TMEM97, NO1, enhanced MDA-MB-231 cell death and reduced the TNBCs proliferation and migration, supporting the relevance of the protein Sigma-2 in the physiology of triple-negative breast cancer cells.
Abstract
(1) Background: The structure of the Sigma 2 receptor/TMEM97 (σ2RTMEM97) has recently been reported. (2, 3) Methods and results: We used genetic and biochemical approaches to identify the molecular mechanism downstream of σ2R/TMEM97. The novel σ2R/TMEM97 fluorescent ligand, NO1, reduced the proliferation and survival of the triple negative breast cancer cell lines (TNBC: MDA-MB-231 and MDA-MB-468 cell lines), due to NO1-induced apoptosis. Greater bioaccumulation and faster uptake of NO1 in MDA-MB-231 cells compared to MCF10A or MCF7 cell lines were also shown. Accordingly, elevated σ2R/TMEM97 expression was confirmed by Western blotting. In contrast to NO1, other σ2R/TMEM97 ligands, such as SM21 and PB28, enhanced MDA-MB-231 cell proliferation and migration. Store-operated calcium entry (SOCE) is crucial for different cancer hallmarks. Here, we show that NO1, but not other σ2R/TMEM97 ligands, reduced SOCE in MDA-MB-231 cells. Similarly, TMEM97 silencing in MDA-MB-231 cells also impaired SOCE. NO1 administration downregulated STIM1-Orai1 interaction, probably by impairing the positive regulatory effect of σ2R/TMEM97 on STIM1, as we were unable to detect interaction with Orai1. (4) Conclusion: σ2R/TMEM97 is a key protein for the survival of triple negative breast cancer cells by promoting SOCE; therefore, NO1 may become a good pharmacological tool to avoid their proliferation.
1. Introduction
Cancer cell proliferation results from a dysregulated cell cycle and an impaired cell-death signaling mechanism, where changes in the cytosolic free-Ca2+ concentration play a relevant role. Store operated Ca2+ entry (SOCE) is considered as a major Ca2+-entry mechanism in nonelectrically excited cells; it is regulated by emptying of the intracellular Ca2+ stores, such as the endoplasmic reticulum (ER). Enhanced SOCE has been reported in different cancer types, including human colorectal cancer, osteosarcoma, and ovary carcinoma [1,2]. In addition, SOCE remodeling, due to changes in the expression of its key molecular components, has been also evidenced in several types of cancer, such as colorectal cancer and oral/oropharyngeal squamous cell carcinoma [3]. In different breast cancer cell lines, including the estrogen receptor positive, MCF7, or the triple negative breast cancer cell line (TNBC), MDA-MB-231 cells, SOCE has been reported to be enhanced as compared to nontumoral cell lines [4,5]. In MCF7 cells, SOCE depends on STIM1, STIM2, and Orai3, whereas in MDA-MB-231 cells, STIM1 activates Ca2+ entry through Orai1 [4,6]. Previous reports in MDA-MB-231 cells showed an enhanced expression of Orai1 [4]. Furthermore, STIM1 expression silencing attenuated the ability of MDA-MB-231 cells to proliferate and migrate in vivo [7]. In agreement with this, Orai1 silencing in MDA-MB-231 cells impaired proliferation and metastasis [8,9]. Finally, a recent study using a new synthetic antagonist of Orai1 (triazole derivative compound) demonstrated a functional role of this channel in MDA-MB-231 cell proliferation, subsequently reinforcing the relevance of SOCE in cancer progression [10]. It is worth noting that STIM1 was found to be overexpressed in samples from breast cancer patients [7,11].
Sigma receptor (σR) family members were initially described as potent neuronal opioid receptors. The administration of their specific agonists was shown to be particularly efficient in the treatment of neuroleptic patients, and useful in the therapy of the schizophrenia [12,13,14]. The existence of two members within this family, σ1R and σ2R, was discovered on the basis of their different pharmacological profiles. Recently, σ2R was identified as TMEM97, which is, at present, described as a cholesterol transport regulator [15], but controversy regarding its structure and identity remains [16]. Thus, chemical synthesis of novel σ2R/TMEM97 ligands will be an emerging scientific field, since this protein was reported to be highly expressed in several cancer cell types. Interestingly, the current evidence indicates that the use of different agonists of σRs downregulates cell proliferation [17,18]. In fact, it has been proposed that agonists of both σ1R and σ2R/TMEM97 are efficient antitumor drugs [19,20]. Regarding the role of σR/TMEM97 in breast cancer, it has been recently described that the protein family involved in DNA damage, Poly (ADP-ribose) polymerase, and σR/TMEM97 might share the same signaling pathway in order to impair breast cancer cell proliferation [21]. Furthermore, the development of new labelling probes for σ2R/TMEM97 is an emerging hot-topic due to their relevance as diagnostic imaging tools for detecting breast solid tumors [22].
A role for σ2R/TMEM97 in the intracellular Ca2+ homeostasis has been suggested, but it has yet to be investigated [23,24]. Firstly, it was reported that incubation of human neuroblastoma SK-N-SH cells with the σ2R ligands like CB-64D, CB-64L, JL-II-147, BD737, LR172, BD1008, haloperidol, reduced-haloperidol, and ibogaine evoked a rise in cytosolic Ca2+ concentration in the absence and presence of extracellular Ca2+. Ca2+ mobilization by activation of σ2R was mediated by empting both thapsigargin (TG)-sensitive and -insensitive reservoirs [23]. The σ2R agonist, F281, was able to mobilize Ca2+ from the ER and mitochondria in SK-N-SH cells [24]. Furthermore, it was reported that σ2R/TMEM97 may be a negative regulator of voltage-activated Ca2+ channel in neurons [25]. On the other hand, the role of σ2R/TMEM97 on Ca2+ homeostasis in triple negative breast cancer cells remains largely unexplored. Here, we aim to elucidate the regulation of SOCE by NO1, a novel σ2R/TMEM97 ligand, in the triple negative breast cancer cell line, MDA-MB-231. Our results indicate that NO1 downregulates SOCE probably by impairing the interaction of σ2R/TMEM97 with STIM1, which may be required for its interaction with Orai1. The incubation of MDA-MB-231 cells with NO1 results in the attenuation of cell proliferation and migration, due to the induction of apoptosis via caspase-9 activation that was also observed in these cells.
2. Results
2.1. σ2R/TMEM97 Is Overexpressed in Breast Cancer Cell Lines
The overexpression of σ2R/TMEM97 has previously been reported in certain cells isolated from different cancer types [26]. As the structure of this protein has long been controversial [27,28,29], we firstly analyzed the expression of σ2R/TMEM97 by WB using a specific anti-TMEM97 antibody (see Figure 1a, n = 6), which has been reported to enhance protein expression in MDA-MB-231 cells, as compared to the MCF10A and MCF7 cell lines. Additionally, we took advantage of the fluorescent property of NO1, a novel σ2R/TMEM97 ligand (NO1: (2-{6-[2-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-3,4-dihydroisoquinolin-1(2H)-one-5-yloxy]hexyl}-5-(dimethylamino)isoindoline-1,3-dione), which was recently designed as a σ2R specific fluorescent ligand (Ki: 10.2 ± 2.4 nM; while its Ki for σ1R is over 5000 nM) [30]. Thus, MCF10A, MCF7, and MDA-MB-231 cells were incubated at room temperature with NO1 (100 nM) for 5 min. Then, the cells were observed under confocal microscopy (Figure 1b, n = 4). As depicted in Figure 1b, we confirmed the enhanced NO1 fluorescence bioaccumulation derived from the elevated presence of σ2R/TMEM97 in MDA-MB-231 cells as compared to MCF10A cells. Next, NO1 cell uptake was analyzed using a spectrofluorophotometer, which revealed an increase in NO1 fluorescence of 46.6 ± 10.4% in MDA-MB-231 cells respect to MCF10A cells (Figure 1c, n = 5; p < 0.01). In addition, both cell lines were exposed to NO1 (100 nM) at room temperature, and we monitored the dye uptake capability of the different cell types for 30 min with an epifluorescent microscope. As evidenced by comparing the results shown in the Video S1 and Video S2, we observed that NO1 was more quickly incorporated and redistributed into the cytosol of the MDA-MB-231 cells. This observation confirms the images obtained by confocal microscopy, in which we incubated the cells with NO1 for shorter time-periods. In fact, NO1 incorporation in MCF10A became evident after a longer exposition period (around 20 min). In contrast to MDA-MB-231 cells, MCF10A cells did not redistribute the dye into the different intracellular locations or organelles, and therefore, NO1 remained largely accumulated near the plasma membrane (see Video S1 vs. Video S2). Therefore, these results showing enhanced σ2R/TMEM97 expression in cancer cells agree with previous findings obtained using different experimental approaches [26,31].
2.2. σ2R/TMEM97 Ligands Alter TNBC Cell Proliferation and Migration
As observed in the supplementary videoclips, NO1 significantly altered the morphology of the MDA-MB-231 cells as compared to MCF10A that remained almost unaltered (Video S1 & Video S2). Hence, we examined whether σ2R/TMEM97 was required for MDA-MB-231 cell function. This issue was investigated by monitoring the BrdU accumulation in cells using an TECAN M200 Infinite pro ELISA plate reader (Tecan Trading Ltd, Mannedorf, Switzerland) plate reader device and σ2R/TMEM97 ligands, such as NO1, SM21, and PB28. As shown in Figure 2a, MDA-MB-231 cells cultured for 48 h in the presence of the SM21 (100 nM), which was previously described as a σ2R/TMEM97 antagonist, showed an increase of 265.0 ± 14.0% in BrdU staining, as compared to the values observed at the beginning of the experiments (time 0 h). Interestingly, cell cultures under control conditions exhibited an increase in BrdU staining of 140.0 ± 14.0% with respect the value found at time 0 (Figure 2a, black trace); thus, SM21 enhanced MDA-MB-231 cell proliferation. Additionally, we incubated the cells with PB28, a previously described σ2R/TMEM97 agonist that may also act as σ1R antagonist. In fact, according to the literature, PB28 acts as a σ2R/TMEM97 ligand and evokes cell death in several cancer cell lines such as pancreatic cancer cells [18,32,33].
Incubation of MDA-MB-231 cells for 48 h with PB28 (1 nM) significantly increased cell growth. PB28 treatment enhanced cell growth more than SM21 (see dark-grey traces in Figure 2a,b). Cell treatment with a combination of both ligands (SM21 + PB28) resulted in a quick increase in cell growth at 24 h; however, thereafter, a slight but not significant decrease in the cell count was found at 48 h. These results led us to conclude that interference of the σ2R/TMEM97 activity modifies the MDA-MB-231 cell proliferation. Finally, to determine the efficiency of NO1 as a possible antiproliferative drug in TNBC cells lines, both MDA-MB-231 and MDA-MB-468 cells were grown as previously described in the absence or presence of NO1 (100 nM). Our results indicate that treatment with NO1 resulted in a significant decrease in cell proliferation of both cell lines (Figure 2c,d). MDA-MB-468 cells have substantial differences as compared to MDA-MB-231 cells, since the former were derived from a noncaucasic patient, representing a much more aggressive type of breast tumor. Finally, the characteristic alteration of the RAS family of genes described in the MDA-MB-231 cells has not been reported for MDA-MB-468 cells [34].
Next, we evaluated the possible role of σ2R/TMEM97 in the ability of MDA-MB-231 cells to migrate. Migration was assessed using the wound-healing assay as described elsewhere [2]. This protocol revealed that SM21 (100 nM) evoked a rapid close up of the scratch at 12 h; meanwhile, small gaps between cells could still be observed under control conditions at that time point (Figure 2e; middle panels versus left hand side panels and the beside bar graph). By contrast, incubation of MDA-MB-231 cells with NO1 (100 nM) for 5 min before the scratch was enough to significantly inhibit the MDA-MB-231 cell migration, as evidenced by the wide gap observed after 12 h of scratch (Figure 2e; left hand side panel vs. right hand side panel and the beside bar graph). This demonstrates that the σ2R/TMEM97 ligand, NO1, reduced cell migration; meanwhile, SM21 has the opposite effect in migration. Altogether, these results reveal a relevant functional role σ2R/TMEM97 on triple negative MDA-MB-231 breast cancer cells which agrees with previous results obtained in other cell models, as well as with different σ2R/TMEM97 agonists [35,36].
2.3. NO1 Promotes Cell Death and Apoptosis in MDA-MB-231 Cells
Previous studies have reported antitumoral effects of σ2R/TMEM97 ligands [21,37,38]. In our experiments, incubation of MDA-MB-231 cells with NO1 for 30 min caused membrane blebbing and cell morphology disruption that were less evident in MCF10A (see Video S1 and Video S2), but also a reduction in the MDA-MB-231 cell proliferation and migration capabilities (Figure 2). Therefore, we speculate about the possible antitumoral action of NO1. Firstly, we evaluated the propidium iodide (PI) staining of MCF10A cells, MCF10A cells artificially overexpressing TMEM97, and MDA-MB-231 cells. Therefore, cells were cultured on coverslips for 48 h to facilitate cell growth, attachment, and artificial expression of TMEM97, which was evidenced by the positive fluorescence derived from its YFP-tag. Next, we replaced the culture medium with Hepes buffer saline (HBS) supplemented with propidium iodide (PI, 4 μM). Then, cells were placed for 45 min at 37 °C inside the incubator, and NO1 (100 nM) or the vehicle were added to the extracellular medium for the last 30 min of incubation. As shown in Figure 3a,b, treatment with NO1 enhanced PI staining. An increase in the number of cells positively stained with PI, i.e., 5 times more cells, were found in NO1-treated MDA-MB-231 cells compared to the untreated cells (white bar in Figure 3a). In addition, NO1 administration to MCF10A resulted in enhanced PI loading, but the increase in PI staining was lower than that in NO1-treated MDA-MB-231 cells (See Figure 3b,c and histogram in Figure 3a).
Interestingly, the percentage of MCF10A positively stained with PI upon NO1 administration increased very significantly upon overexpression of TMEM97 (Figure 3a,c). An analysis of the fluorescence images emitted by NO1 and YFP-TMEM97 overexpressed in MCF10A revealed a relatively high degree of colocalization (Figure S1). These data indicate that NO1 may be evoking cell death by interacting with σ2R/TMEM97; this would explain the aforementioned reduction in the migration capability of MDA-MB-231 cells. In order to extend our knowledge regarding the mechanism underlying the effect of NO1 on MDA-MB-231 cells, we investigated the possible proapoptotic effect of NO1 on MDA-MB-231 cells by flow-cytometry and using the BrdU-based TUNEL technique described in the Material and Methods section.
As depicted in Figure 4a, the incubation of MDA-MB-231 cells for 5 min with NO1 (100 nM) evoked a significant increase of 24.0 ± 8.0% (p < 0.01; n = 4) in the number of apoptotic cells as compared to untreated cells.
In order to rule out possible NO1 off targets which were different from σ2R/TMEM97, we analyzed the effect of NO1 on MCF10A cells (Figure 4b), which presented a low level of σ2R/TMEM97 expression, as previously evidenced in Figure 1. As expected, NO1 (100 nM) administration for 5 min to MCF10A cells did not evoke the activation of apoptosis (2.0 ± 5.0 %; p > 0.05; n = 6). Interestingly, cisplatin treatment did not alter the percentage of apoptotic cells (2.0 ± 3.0%; p > 0.05; n = 6), and only the combination of both drugs was able to evoke an increase in the percentage of the MCF10A apoptotic cells, but it lacks of statistical significance (2.0 ± 3.0%; p > 0.05; n = 6). Overall, the percentage of apoptotic cells observed in the experiments using MCF10A were less significant than those observed in MDA-MB-231 cells (compare histograms of Figure 4a,b).
Next, we analyzed the downstream cell death mechanisms induced by the incubation of MDA-MB-231 cells with NO1. Thus, MDA-MB-231 cell samples were incubated for 5 min with 100 nM of NO1, or were kept under resting conditions. Subsequently, all the samples were solved by Western blotting using the anticaspase 9, anti-GRP78 and antiphospho-eiF2α antibodies in order to ascertain whether NO1 might activate either mitochondrial-dependent [38,39] or ER stress-dependent apoptotic pathways [40,41], respectively. Additionally, membranes were probed with anti-LC3 antibody to ascertain the LC3II/LC3I ratio that is indicative of the possible activation of autophagy in response to NO1 [42]. σ2R/TMEM97 was not localized in the mitochondria, as reflected by the lack of NO1 colocalization with mitotracker both in resting and in TG-activated cells (see confocal images in the Figure S2a,b, respectively). However, NO1 interfered with σ2R/TMEM97 activity, and subsequently, evoked the activation of a mitochondrial-dependent apoptotic pathway. This fact was evidenced by the increase of 16.0 ± 8.0% observed in the content of active caspase 9 (35 kDa), which was in parallel with the decrease in the content of the inactive procaspase 9 (47 kDa) (Figure 5a; p < 0.05; n = 3). In contrast, NO1 did not activate the other cell death pathways analyzed here, such as ER stress or autophagy (Figure 5b,c).
In addition, we evaluated the caspase pathways involved in the NO1-evoked apoptosis using the specific fluorogenic substrates for caspase 9, 3, and 8 [43]. As depicted in Figure S3, all of the used caspase substrates increased their fluorescence upon cell incubation with NO1 (100 nM). To ascertain possible interference derived of the NO1 autofluorescence in these results, we used internal controls where cells were incubated with NO1 but not with the fluorogenic substrates. We also added NO1 directly to the reaction buffer but lacking cell lysates. The resulting fluorescence obtained in these internal controls was used to correct the fluorescence emitted by the caspase substrates in each experiment. The magnitude of the fluorescence emitted by the caspase substrates were much greater than NO1 fluorescence. Data shown in Figure S3 revealed that caspase 9 would first be activated as a result of the NO1 incubation; this conclusion is based on the fact that a significant increase in the caspase 9 substrate fluorescence was evidenced as soon as 5 min after NO1 addition to the cells, which did not significantly change thereafter, independently of the incubation period (Figure S3a). The latter might be due to the interference with the mitochondrial activity previously reported when using other σ2R/TMEM97 ligands [24]. Accordingly, caspase 3 was activated after incubating cells with NO1 for 5 min, but to a smaller extent than caspase 9 (Figure S3b). The fluorescence of the caspase 3 and 8 substrates increased significantly after 30 min of cell incubation with NO1 (see Figure S3b,c). These caspases have been reported to be activated downstream of caspase 9 in other cell types [44]. Further evidence of the involvement of caspase 9 in the apoptotic mechanism driven by NO1 was obtained by preincubating the MDA-MB-231 cells for 90 min with 40 μM of the caspase 9 inhibitor (Z-LEHD-FMK), which significantly attenuated the effect of NO1 (Figure S4).
2.4. σ2R/TMEM97 Is Required for SOCE Activation in MDA-MB-231 Cells
Proliferation of breast tumor cells strongly depends on the Ca2+-homeostasis, as evidenced by the fact that silencing of Orai1, the main component of the store operated Ca2+ entry (SOCE), decreased the proliferation of the MDA-MB-231 cells [9,45]. In addition, calcineurin activation due to the Ca2+-entry through Orai1 has been reported to dephosphorylate and activate the proproliferative transcription factor NFAT1 [46,47]. Interestingly, the use of σ1R and σ2R ligands was shown to alter the Ca2+ homeostasis in SK-N-SH neuroblastoma cells [23]. Thus, considering the elevated expression of σ2R/TMEM97 in the MDA-MB-231 cells, we investigated its possible role in intracellular Ca2+homeostasis. We observed that the incubation of fura-2-loaded MDA-MB-231 cells with NO1 (100 nM for 5 min) did not produce significant changes in the TG-evoked Ca2+ release from the intracellular pools (Figure 6a). By contrast, NO1 significantly reduced SOCE by 17.0 ± 12.0% (Figure 6a; p < 0.05; n = 6). NO1 was able to downregulate SOCE, even when this mechanism was previously activated due to cell stimulation with TG for 3 min before the addition of the σ2R/TMEM97 ligand. As observed in Figure 6b, a reduction of 34.5 ± 1.0% (p < 0.001, n = 6) was found under these experimental conditions. Interestingly, the preincubation of MDA-MB-231 cells for 5 min with SM21 overcame the inhibition of SOCE evoked by NO1 (95.5 ± 2.0%; p > 0.0 5, n = 6). We further explored the role of σ2R/TMEM97 in SOCE by either overexpressing TMEM97 (Figure 6c) or by transfection of a siRNA TMEM97 (Figure 6d) in MDA-MB-231 cells. Upon confirming the transfection either by fluorescent microscopy or WB, TMEM97 overexpression resulted in an increase of 56.0 ± 1.8% in SOCE (p < 0.001, n = 4); meanwhile, silencing of TMEM97 reduced significantly the TG-evoked SOCE, i.e., by 24.8 ± 14.5% (p < 0.05, n = 4).
MCF10A cells expressed a very low amount of σ2R/TMEM97 (see Figure 1). Therefore, we incubated cells with SM21 (100 nM for 5 min) and, as expected, SM21 did not modify either the TG-evoked Ca2+ release from the intracellular stores or SOCE in these cell lines (See Figure S5a; p > 0.05, n = 6). In contrast, in MDA-MB-231 cells that expressed a high amount of σ2R/TMEM97, we observed an increase of 44.0 ± 14.0% (p < 0.001, n = 8) in the TG-evoked Ca2+ entry after SM21 administration to MDA-MD-231 cells as compared to the values found in cells treated with the vehicle (See Figure S5b, p < 0,001, n = 6).
Interestingly, SM21 was unable to activate SOCE per se, suggesting that this σ2R/TMEM97 ligand specifically regulates SOCE upon its activation with TG (Figure S5c). Elevated SOCE in the presence of SM21 could also be explained by a possible interference of σ2R/TMEM97 with the plasma membrane Plasma membrane Ca2+-ATPase (PMCA) pumps, because we estimated SOCE by the determination of cytosolic Ca2+ concentrations, a parameter dependent on the balance between Ca2+ entry and Ca2+ clearing mechanisms [48,49]. In order to confirm this hypothesis, fura-2-loaded MDA-MB-231 cells were suspended in a Ca2+-free HBS medium and preincubated for 5 min with either the vehicle or SM21 (100 nM), subsequently, with 2 µM of TG (to block Ca2+ reuptake in the endoplasmic reticulum, ER) and 100 nM of ionomycin (the Ca2+ ionophore used for facilitating the Ca2+ escape from intracellular stores). This protocol induced a transient increase in the cytosolic Ca2+ concentration. The Ca2+ decay constants were not altered in the absence and presence of SM21, and therefore, the changes observed in the Ca2+ extrusion rate derived from PMCA activity were not affected by σ2R/TMEM97 activity (Figure S6). Finally, we preincubated the cells with PB28 for 5 min before activating SOCE with TG, which resulted in an increase of 57.9 ± 27.5% and 51.6 ± 21.5% in both the TG-evoked Ca2+ release and the TG-evoked SOCE, respectively. These findings suggest that σ2R/TMEM97 is required for the activation of SOCE in MDA-MB-231 cells. We further explored the role of NO1 and SM21 in the association between the components of the SOCE, due to the fact that both specifically interfere with SOCE without affecting Ca2+ release, and furthermore, that both are very specific ligands of σ2R/TMEM97. By contrast, the effects of PB28 could be explained by possibly off-target effects, since it is reported to bind σ1R, and neither alters Ca2+ release nor SOCE in MCF7 (cell type expressing low σ1R) [32]. In fact, other authors have previously reported that this drug interferes with σ1R [50], which is highly expressed in MDA-MB-231 cells [51]. The latter would explain the fact that in our cell model, PB28 was observed to evoke Ca2+ release from intracellular stores, and, at the same time, to avoid the negative role of σ1R in SOCE that has recently been described in other cell types [52]; therefore, a PB28-dependent increase in SOCE would have a positive effect upon MDA-MB-231 cell proliferation, as presented above.
2.5. σ2R/TMEM97 Interacts with STIM1 But Not with Orai1 during SOCE Activation
SOCE is driven by the interaction between the ER Ca2+ sensor, STIM1, and the specific Ca2+ channel, Orai1 [53,54,55]. Hence, we sought to determine whether σ2R/TMEM97 might be interacting and regulating these key proteins during the activation of SOCE. Firstly, we explored the association between σ2R/TMEM97 and STIM1 in MDA-MB-231 cells by immunoprecipitating the Ca2+ sensor with a specific anti-STIM1 antibody, followed by staining the immunoprecipitates with NO1, as described in the Material and Methods section. Analysis of the NO1 fluorescence revealed that TG enhanced the STIM1-σ2R/TMEM97 interaction three fold (Figure 7a; p < 0.001, n = 6). Treatment of MDA-MB-231 cells with SM21 (5 min with 100 nM) reduced significantly this interaction (p < 0.001, n = 6), which might explain why preincubation with SM21 prevents the effect of NO1 on SOCE, as described in Figure 6b.
Previous data have suggested that σ2R/TMEM97 might also be present in the plasma membrane of the cells, and may facilitate the transport of cholesterol toward the cytosol [26,56,57]; therefore, we further explored the possible interaction between σ2R/TMEM97 and Orai1 at this location. As depicted in Figure 7b, MDA-MB-231 cells were either stimulated with TG or left untreated, and subsequently, loaded for 5 min with NO1 (100 nM) before fixating with ice-cold paraformaldehyde. Subsequently, the Orai1 content was evaluated by staining the fixed cells with an anti-Orai1 antibody and a fluorescent secondary antibody. Confocal microscopy analysis revealed that σ2R/TMEM97 did not colocalize, either in resting or in cells stimulated with TG (Figure 7b), with Orai1. Next, in order to ascertain whether σ2R/TMEM97 plays a role in the interaction between STIM1 and Orai1, we tested the role of NO1 and SM21 in the co-immunoprecipitation between both proteins. As depicted in Figure 7c, treatment of MDA-MB-231 cells with TG enhanced the STIM1/Orai1 coupling by 1.6 ± 0.6 -fold increase (p < 0.05; n = 6). Preincubation with NO1 did not modify the interaction between the proteins in resting, but significantly reduced TG-evoked STIM1/Orai1 coupling (0.85 ± 0.1 -fold increase compared to the values found in resting cells; Figure 7c). In addition, treatment with SM21 (100 nM) for 5 min slightly enhanced the TG-evoked STIM1/Orai1 coupling, but the differences when compared with nontreated cells lacked statistical significance (0.4 ± 0.2; p > 0.05, n = 8–10; Figure 7d). Altogether, these results suggest that the addition of NO1 might downregulate σ2R/TMEM97 activity, and thus, NO1 may impair SOCE by affecting the interaction of the ICRAC components, as was the case when we artificially silenced this protein using the siRNA against TMEM97 (Figure 6d).
Finally, to consolidate the latest results, we used the neuroblastoma NG115-401L cell line that expresses a scarce amount of STIM1 [58]. NG115-401L expressed TMEM97, and although it is significantly elevated with respect to the amount found in MCF10A cells, the values of TMEM97 found in NG115-401L were much smaller than those observed in MDA-MB-231 cells (Figure 8a). After 30 min of incubation with NO1 (100 nM), the NG115-401L cells presented low NO1 bioaccumulation, and consequently, exhibited a negligible NO1-derived fluorescence emission (see Video S3). This low bioaccumulation of NO1 may explain why these cells did not present significant changes in their morphology upon incubation with the drug for that time period, but also, it would explain the low PI staining (Figure 8a,c left-hand side images; NG115-401L mock) upon analysis of the cells by using the same protocol as in Figure 3. Additionally, the overexpression of STIM1 in this cell model reconstitutes normal SOCE, as previously evidenced by our research group and others [59,60]. Interestingly, STIM1 overexpression resulted in an increase in the NO1 intracellular redistribution in NG115-401L cells, which is parallel with an increase in the number of cells that are positively stained with PI (see Figure 8b dotted bar, and Figure 8c right-hand side images, NG115-401L STIM1). These results indicate that in the absence of STIM1, NO1 has less cytotoxic effect, thereby supporting the hypothesis that σ2R/TMEM97 controls STIM1 and SOCE, as suggested by the elevated rate of colocalization between NO1 and STIM1 in NG115-401L cells where we previously overexpressed STIM1, followed by incubation for 30 min with NO1 (Figure S1b).
3. Discussions
In the present study, we examined the antiproliferative effect of NO1 in the triple negative breast cancer cell lines, MDA-MB-231 and MDA-MB-468 cells, and the downstream mechanisms of σ2R/TMEM97. Our results indicate that SM21 and PB28, both σ2R/TMEM97 ligands, facilitate the proliferation and migration of MDA-MB-231 cells; by contrast, the addition of the NO1 impairs migration and evokes cell death by activating apoptosis via caspase 9 activation. Our results indicate that σ2R/TMEM97 plays a regulatory role in SOCE, as TMEM97 overexpression enhances SOCE while TMEM97 silencing reduces it, as does NO1.
The inhibitory effect of NO1 on SOCE was consistent with its effect impairing STIM1/Orai1 interaction, and probably, by promoting the dissociation of the complex between σ2R/TMEM97 and STIM1. As a result, NO1 administration to MDA-MB-231 cells evoked a reduction in cell proliferation and migration that agrees with previous investigations reported in the literature using other ligands of σ2R/TMEM97 [17,18,36,61]. In line with our observations, σ2R/TMEM97 was shown to be overexpressed in different cancer types, and even in patients with breast cancer [31,62,63]. Here, we confirmed the enhanced σ2R/TMEM97 expression in the triple negative breast cancer cell line MDA-MB-231 cells by different experimental approaches.
A possible regulatory role of σ2R/TMEM97 in the intracellular Ca2+ homeostasis has already been suggested in the human neuroblastoma cells, SK-N-SH cell line, using high concentrations of ligands BD737 and CB-64D [23]. However, according to the pharmacological drug profiles described by these authors, σ1R might also be affected by these drugs at the concentration used [23]. It is worth noting that those σ2R/TMEM97 ligands failed to release Ca2+when the Ca2+ stores were previously depleted with TG, indicating that the Ca2+ source is the ER, leading us to again assume that σ1R might be involved in this process. In fact, σ1R was localized in the mitochondrial-associated membranes complexes, and subsequently, may regulate Ca2+ depletion from the ER and mitochondrial overload [64]. Furthermore, it has been shown that σ1R associates with STIM1 in the ER, thereby acting as its negative regulator, which would explain the negative role of σ1R in SOCE. We found here that among the σ2R/TMEM97 ligands used in MDA-MB-231 or MCF10A (in case of SM21), two of them, SM21 and NO1, failed to evoke Ca2+ release from the intracellular Ca2+ stores at the concentrations assayed (100 nM) [65]. In addition, the σ2R/TMEM97 ligand, NO1, did not alter the Ca2+ content within the intracellular stores of MDA-MB-231 cells, which disagrees with the results obtained using the F281 (σ2R agonist) in SK-N-SH cells [24]. According to the latter, it is likely that σ2R/TMEM97 has different roles in different cell lineages. In fact, a similar dual role of σ1R in Ca2+ homeostasis can be found in the literature; thus, although σ1R has been shown to be a negative regulator of SOCE in SK-N-SH cells, other authors have demonstrated that the addition of the σ1R agonist, pentazocine, enhanced SOCE in SK-N-SH and MCF7 (artificially overexpressing σ1R) cell lines, while BD1063 (σ1R antagonist) reduced Ca2+ entry. Similarly, PB28 did not promote SOCE in MCF7, but this σ2R/TMEM97 ligand enhanced SOCE in MDA-MB-231 cells which can be explained by the elevated σ1R content in these cells, compared to those of MCF7, that express a low amount of σ1R [66]. Enhanced SOCE evoked by PB28 could be explained by the dual role of the drug over σ1R and σ2R/TMEM97. While activating σ2R/TMEM97, a positive regulator of SOCE, it is simultaneously inhibiting the SOCE negative regulator, σ1R, which would result in the exacerbated SOCE demonstrated in Figure S5d, and in the enhanced proliferation shown in Figure 2b. Similarly, SM21 might be activating SOCE, despite the fact that a slight increase in the interaction between STIM1 and Orai1 was demonstrated (Figure 7d). In line with this latter observation, SM21 would increase MDA-MB-231 cell proliferation. In contrast, NO1 would downregulate SOCE by interacting with σ2R/TMEM97, and perhaps also by impairing its association with STIM1. Although speculative, σ2R/TMEM97 might displace σ1R from STIM1, thus favoring its interaction with Orai1, which would be a worthy object of future research.
In the breast cancer cell lines MCF7 and MDA-MB-231 cells, the silencing of Orai3 and Orai1 expressions reduced cell proliferation and tumorigenic properties [4,9,10,45]. In the present study, we report for the first time that a ligand of σ2R/TMEM97, NO1, enhanced MDA-MB-231 cell death and reduced the TNBCs proliferation and migration. Our results agree with previous publications regarding other σ2R/TMEM97 ligands, such as WC-26, SV119, and RHM-138, that were shown to evoke cell death of the EMT-6 and MDA-MB-435 cell lines [26]. The authors claimed that these σ2R/TMEM97 agonists induced both mitochondrial-dependent apoptosis and the activation of autophagy, which occurs through the synthesis and processing of LC-3, subsequently reducing mTOR expression [26]. In MDA-MB-231 cells, NO1 does not evoke the activation of autophagy, as concluded by the fact that no significant changes in the LC3II/LC3I ratio were observed (see Figure 5). Finally, in order to determine the mechanism through which σ2R activity might impair breast cancer cell survival, we analyzed its possible localization within the mitochondria. σ2R/TMEM97 activation might mobilize Ca2+ from mitochondria [24] and evoke mitochondrial membrane potential uncoupling and caspase-dependent apoptosis activation, as previously reported [18,24]. By using confocal microscopy and the fluorescent σ2R/TMEM97 ligand (NO1), we failed to localize this protein within the mitochondria, either under resting conditions or during SOCE activation with TG. Nonetheless, NO1 was able to induce procaspase 9 cleavage into the active caspase 9 (Figure 5a and Figure S3). Caspase 9 activation is widely used as a cell marker to monitor the activation of mitochondria-dependent apoptosis [67,68]; this observation agrees with previous ones using σ2R/TMEM97 agonists [17]. In this sense, the σ2R agonist (F281) reduces ATP concentration in a time- and concentration-dependent manner in SK–N–SH cells, which has been attributed to its ability to interfere with the mitochondrial function, and subsequently, to attenuate ATP synthesis [24]. The regulation of SOCE by the mitochondria and vice versa have been widely described [69,70,71]. Therefore, σ2R/TMEM97 may facilitate SOCE by two different mechanisms, firstly facilitating STIM1 activation, and subsequently, favoring its contact to Orai1, but it may also enhance mitochondrial function, which would lead to mitochondrial Ca2+-sequestering in the proximity of the channel in the membrane that has been reported to delay the signaling of SOCE downregulation by Ca2+ [72,73,74]. It is worth noting that in NG115-401L, a model mostly lacking STIM1, NO1 was unable to evoke cell death unless STIM1 was overexpressed, which reinforces our presumption that STIM1 is an intracellular target of NO1. In line with this observation, we suggest that the expression of STIM1 and σ2R/TMEM97 may be indicative of the efficiency of the NO1 in impairing the progression of certain types of cancers, but further experiments are required to confirm this idea. The inhibition of σ2R/TMEM97 in both TNBC leads to the induction of apoptosis and the reduction of cell proliferation, thus supporting the relevance of this protein in the physiology of triple negative breast cancer cells.
In summary, we described an elevated σ2R/TMEM97 expression in MDA-MB-231 cells, which might be involved in the regulation of cell proliferation through the enhancement of SOCE (see Figure 9). NO1 impairs the role of σ2R/TMEM97 in SOCE, thus evoking MDA-MB-231 cell death.